[  概要   |   展销前置会   |   1日目   |   2日目   |   3日目   |   Catalog(PDF)  ]

SESSIONS INCLUDE

• DRIVERS, CHALLENGES AND IMPLEMENTATION

• IMPACT OF BIOMARKERS AND MOLECULAR PROFILING ON DISCOVERY

• AND DEVELOPMENT

• CHOOSING AN IMAGING MODALITY FOR BOTH INTERNAL DECISION

• MAKING AND REGULATORY APPROVAL

• TRANSLATIONAL ONCOLOGY

• PHARMACEUTICAL EXPLORATION

PLENARY KEYNOTE SPEAKERS

Diagnosing the Disease: Disruptive Innovation in Healthcare
Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School

Disruption of the Pharmaceutical Industry: Moving from Products to Solutions
Elizabeth L. Bewley, MBA, Vice President, Strategic Planning, Johnson & Johnson Health Care Systems Inc.

Risk Diagnosis for Disease Prevention
C. Thomas Caskey, M.D., F.A.C.P., Director and Chief Executive Officer, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center

PANELS AND BREAKOUT DISCUSSIONS

• Panel Discussion: What Does It Take to Qualify a Biomarker as a Surrogate Endpoint?

• Breakout Discussion 1: Translational Science Across the Globe: Needs, Opportunities and Challenges

• Breakout Discussion 2: Use of Biomarkers to Make Go / No-go Decisions ・Are We Ready?

• Breakout Discussion 3: How Translational Medicine Can Contribute to Early R&D Productivity Using a Standards of Evidence Approach